MarketCap
Facebook
X
Telegram
Solid Biosciences Total Assets | SLDB
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Solid Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 233 M | 189 M | 165 M | 260 M | 232 M | 171 M | 103 M | 140 M | 76.2 M | 40.6 M | 55.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 260 M | 40.6 M | 151 M |
Quarterly Total Assets Solid Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 421 M | 423 M | 274 M | 308 M | 344 M | 189 M | 212 M | 231 M | 249 M | 165 M | 185 M | 205 M | 230 M | 260 M | 184 M | 208 M | 208 M | 232 M | 249 M | 266 M | 285 M | 171 M | 171 M | 171 M | 171 M | 103 M | 103 M | 103 M | 103 M | 140 M | 140 M | 140 M | 140 M | 76.2 M | 76.2 M | 76.2 M | 76.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 423 M | 76.2 M | 197 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
853 M | $ 3.83 | 0.26 % | $ 210 M |  Canada |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.73 | 0.25 % | $ 3.13 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
76.8 M | $ 6.98 | 5.12 % | $ 104 M |  USA |
 |
Cronos Group
CRON
|
1.2 B | $ 3.29 | 2.81 % | $ 1.26 B | Canada |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
18.3 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
129 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Emergent BioSolutions
EBS
|
1.32 B | $ 6.75 | 6.13 % | $ 361 M | USA |
 |
Evolus
EOLS
|
226 M | $ 7.99 | 1.01 % | $ 515 M | USA |
 |
Harrow Health
HROW
|
399 M | $ 34.21 | 1.09 % | $ 1.26 B | USA |
 |
Bausch Health Companies
BHC
|
26.4 B | $ 5.69 | 0.35 % | $ 2.11 B | Canada |
 |
Pacira BioSciences
PCRX
|
1.26 B | $ 24.91 | 3.45 % | $ 1.11 B | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 13.54 | 0.07 % | $ 1.88 B | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 4.22 | 0.45 % | $ 167 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 7.8 | 0.64 % | $ 281 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 4.11 | 0.91 % | $ 205 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.38 | 2.22 % | $ 356 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
14 M | $ 1.23 | 0.77 % | $ 2.07 M | USA |
 |
Tilray
TLRY
|
2.07 B | $ 3.93 | 2.99 % | $ 3.5 B | Canada |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 2.18 | 0.93 % | $ 25.2 M | USA |
 |
Veru
VERU
|
29.8 M | $ 2.32 | 0.64 % | $ 34 M | USA |
 |
Viatris
VTRS
|
37.2 B | $ 17.02 | 2.22 % | $ 19.5 B | USA |
 |
cbdMD
YCBD
|
10.4 M | $ 0.47 | 1.04 % | $ 1.89 M | USA |
 |
Organogenesis Holdings
ORGO
|
599 M | $ 1.39 | 0.67 % | $ 176 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.86 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Canopy Growth Corporation
CGC
|
1.12 B | $ 0.92 | 0.45 % | $ 274 M | Canada |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.06 | 0.94 % | $ 101 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | - | - | $ 150 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
17.5 M | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
59.9 M | - | - | $ 5.07 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Zomedica Corp.
ZOM
|
127 M | - | -0.21 % | $ 98 M | USA |